Novo Nordisk's stock has dropped 28% year-to-date and 53% over the past 12 months, reaching multi-year low valuations. Despite concerns over macroeconomic uncertainty and weakening demand for obesity drugs, the company remains fundamentally strong with long-term growth prospects in obesity treatment. The recent sell-off is seen as an overreaction, and the stock appears technically oversold, suggesting a potential rebound. Investors with a long-term view may find this a good entry point amid current market volatility.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
